nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—schizophrenia—Valproic Acid—migraine	0.208	1	CpDpCtD
Fluoxetine—HTR2C—migraine	0.0883	0.406	CbGaD
Fluoxetine—SLC6A4—migraine	0.0731	0.336	CbGaD
Fluoxetine—HTR2A—migraine	0.0562	0.258	CbGaD
Fluoxetine—Duloxetine—Propranolol—migraine	0.0515	0.228	CrCrCtD
Fluoxetine—Cinacalcet—Propranolol—migraine	0.0439	0.194	CrCrCtD
Fluoxetine—Isoxsuprine—Propranolol—migraine	0.0384	0.17	CrCrCtD
Fluoxetine—Demexiptiline—Propranolol—migraine	0.0362	0.16	CrCrCtD
Fluoxetine—SIGMAR1—Amitriptyline—migraine	0.0238	0.101	CbGbCtD
Fluoxetine—Bromodiphenhydramine—Amitriptyline—migraine	0.0213	0.0946	CrCrCtD
Fluoxetine—Atomoxetine—Propranolol—migraine	0.0178	0.0787	CrCrCtD
Fluoxetine—ORM1—Propranolol—migraine	0.0173	0.0733	CbGbCtD
Fluoxetine—Orphenadrine—Amitriptyline—migraine	0.0168	0.0743	CrCrCtD
Fluoxetine—ORM1—Amitriptyline—migraine	0.015	0.0634	CbGbCtD
Fluoxetine—SLC6A4—Amitriptyline—migraine	0.0124	0.0524	CbGbCtD
Fluoxetine—HTR2C—Amitriptyline—migraine	0.0104	0.0439	CbGbCtD
Fluoxetine—SLC6A2—Amitriptyline—migraine	0.0104	0.0439	CbGbCtD
Fluoxetine—SLC6A4—Verapamil—migraine	0.00983	0.0416	CbGbCtD
Fluoxetine—HTR2A—Amitriptyline—migraine	0.00934	0.0395	CbGbCtD
Fluoxetine—CYP2B6—Amitriptyline—migraine	0.00643	0.0272	CbGbCtD
Fluoxetine—ALB—Amitriptyline—migraine	0.0063	0.0267	CbGbCtD
Fluoxetine—CYP2B6—Valproic Acid—migraine	0.00586	0.0248	CbGbCtD
Fluoxetine—CYP3A5—Propranolol—migraine	0.00585	0.0248	CbGbCtD
Fluoxetine—CYP2C19—Timolol—migraine	0.0053	0.0224	CbGbCtD
Fluoxetine—CYP2B6—Verapamil—migraine	0.0051	0.0216	CbGbCtD
Fluoxetine—CYP3A5—Amitriptyline—migraine	0.00506	0.0214	CbGbCtD
Fluoxetine—CYP2C19—Propranolol—migraine	0.00472	0.02	CbGbCtD
Fluoxetine—CYP3A5—Valproic Acid—migraine	0.00462	0.0195	CbGbCtD
Fluoxetine—CYP1A2—Propranolol—migraine	0.00436	0.0184	CbGbCtD
Fluoxetine—ABCB1—Timolol—migraine	0.00428	0.0181	CbGbCtD
Fluoxetine—CYP2C19—Amitriptyline—migraine	0.00408	0.0173	CbGbCtD
Fluoxetine—CYP2D6—Timolol—migraine	0.00403	0.0171	CbGbCtD
Fluoxetine—CYP3A5—Verapamil—migraine	0.00402	0.017	CbGbCtD
Fluoxetine—ABCB1—Propranolol—migraine	0.00381	0.0161	CbGbCtD
Fluoxetine—CYP1A2—Amitriptyline—migraine	0.00377	0.016	CbGbCtD
Fluoxetine—CYP2C19—Valproic Acid—migraine	0.00372	0.0158	CbGbCtD
Fluoxetine—CYP2D6—Propranolol—migraine	0.00359	0.0152	CbGbCtD
Fluoxetine—CYP1A2—Valproic Acid—migraine	0.00344	0.0145	CbGbCtD
Fluoxetine—CYP2C9—Amitriptyline—migraine	0.0034	0.0144	CbGbCtD
Fluoxetine—CYP2C19—Topiramate—migraine	0.00336	0.0142	CbGbCtD
Fluoxetine—ABCB1—Amitriptyline—migraine	0.0033	0.014	CbGbCtD
Fluoxetine—CYP2C19—Verapamil—migraine	0.00324	0.0137	CbGbCtD
Fluoxetine—CYP2D6—Amitriptyline—migraine	0.00311	0.0131	CbGbCtD
Fluoxetine—CYP2C9—Valproic Acid—migraine	0.0031	0.0131	CbGbCtD
Fluoxetine—CYP1A2—Verapamil—migraine	0.00299	0.0127	CbGbCtD
Fluoxetine—CYP2C9—Verapamil—migraine	0.00269	0.0114	CbGbCtD
Fluoxetine—ABCB1—Verapamil—migraine	0.00262	0.0111	CbGbCtD
Fluoxetine—HTR2A—trigeminal nucleus—migraine	0.00261	0.169	CbGeAlD
Fluoxetine—CYP2D6—Verapamil—migraine	0.00246	0.0104	CbGbCtD
Fluoxetine—CYP3A4—Propranolol—migraine	0.00228	0.00967	CbGbCtD
Fluoxetine—CYP3A4—Amitriptyline—migraine	0.00197	0.00836	CbGbCtD
Fluoxetine—CYP3A4—Valproic Acid—migraine	0.0018	0.00762	CbGbCtD
Fluoxetine—CYP3A4—Topiramate—migraine	0.00162	0.00688	CbGbCtD
Fluoxetine—CYP3A4—Verapamil—migraine	0.00157	0.00663	CbGbCtD
Fluoxetine—SLC6A2—locus ceruleus—migraine	0.00139	0.0902	CbGeAlD
Fluoxetine—SLC6A2—sympathetic nervous system—migraine	0.0011	0.0713	CbGeAlD
Fluoxetine—HTR2A—locus ceruleus—migraine	0.000838	0.0542	CbGeAlD
Fluoxetine—SLC6A2—autonomic nervous system—migraine	0.000741	0.0479	CbGeAlD
Fluoxetine—HTR2A—trigeminal nerve—migraine	0.000686	0.0444	CbGeAlD
Fluoxetine—HTR2A—sympathetic nervous system—migraine	0.000662	0.0429	CbGeAlD
Fluoxetine—HTR2A—cranial nerve—migraine	0.000489	0.0316	CbGeAlD
Fluoxetine—HTR2A—pons—migraine	0.000483	0.0312	CbGeAlD
Fluoxetine—HTR2A—autonomic nervous system—migraine	0.000445	0.0288	CbGeAlD
Fluoxetine—SLC6A2—nerve—migraine	0.000417	0.027	CbGeAlD
Fluoxetine—HTR2A—pineal body—migraine	0.000345	0.0223	CbGeAlD
Fluoxetine—HTR2A—peripheral nervous system—migraine	0.000321	0.0208	CbGeAlD
Fluoxetine—Atomoxetine—HTR1D—migraine	0.000253	0.167	CrCbGaD
Fluoxetine—HTR2A—nerve—migraine	0.00025	0.0162	CbGeAlD
Fluoxetine—Orphenadrine—SCN1A—migraine	0.000234	0.154	CrCbGaD
Fluoxetine—Duloxetine—HTR2C—migraine	0.000234	0.154	CrCbGaD
Fluoxetine—SIGMAR1—trigeminal ganglion—migraine	0.000228	0.0148	CbGeAlD
Fluoxetine—HTR2C—brainstem—migraine	0.000214	0.0139	CbGeAlD
Fluoxetine—SLC6A4—brainstem—migraine	0.000203	0.0131	CbGeAlD
Fluoxetine—HTR2A—blood vessel—migraine	0.000197	0.0127	CbGeAlD
Fluoxetine—HTR2A—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2C—migraine	0.000196	0.0124	CbGpPWpGaD
Fluoxetine—HTR2A—Amine ligand-binding receptors—HTR1D—migraine	0.000196	0.0124	CbGpPWpGaD
Fluoxetine—Duloxetine—SLC6A4—migraine	0.000194	0.128	CrCbGaD
Fluoxetine—SLC6A2—Monoamine Transport—SLC6A4—migraine	0.000192	0.0121	CbGpPWpGaD
Fluoxetine—HTR2A—Amine ligand-binding receptors—HTR2B—migraine	0.000182	0.0115	CbGpPWpGaD
Fluoxetine—SLC6A2—brainstem—migraine	0.000179	0.0116	CbGeAlD
Fluoxetine—HTR2C—Monoamine GPCRs—HTR1B—migraine	0.000163	0.0103	CbGpPWpGaD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—ATP1A3—migraine	0.000161	0.0102	CbGpPWpGaD
Fluoxetine—HTR2C—Monoamine GPCRs—HTR1A—migraine	0.000157	0.00989	CbGpPWpGaD
Fluoxetine—Atomoxetine—HTR1B—migraine	0.00015	0.0991	CrCbGaD
Fluoxetine—Duloxetine—HTR2A—migraine	0.000149	0.0982	CrCbGaD
Fluoxetine—HTR2A—Monoamine GPCRs—HTR1B—migraine	0.000141	0.00892	CbGpPWpGaD
Fluoxetine—HTR2A—neck—migraine	0.000141	0.0091	CbGeAlD
Fluoxetine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HTR2A—migraine	0.000139	0.00875	CbGpPWpGaD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—HTR3A—migraine	0.000137	0.00866	CbGpPWpGaD
Fluoxetine—HTR2C—Amine ligand-binding receptors—HTR1B—migraine	0.000137	0.00864	CbGpPWpGaD
Fluoxetine—HTR2A—Monoamine GPCRs—HTR1A—migraine	0.000136	0.00859	CbGpPWpGaD
Fluoxetine—HTR2C—Monoamine GPCRs—HTR7—migraine	0.000133	0.00837	CbGpPWpGaD
Fluoxetine—HTR2C—Amine ligand-binding receptors—HTR1A—migraine	0.000132	0.00831	CbGpPWpGaD
Fluoxetine—HTR2A—Monoamine GPCRs—HTR2C—migraine	0.000131	0.00829	CbGpPWpGaD
Fluoxetine—ABCB1—blood vessel—migraine	0.000129	0.00834	CbGeAlD
Fluoxetine—ORM1—nervous system—migraine	0.000125	0.00808	CbGeAlD
Fluoxetine—Atomoxetine—HTR2C—migraine	0.000122	0.0808	CrCbGaD
Fluoxetine—ORM1—central nervous system—migraine	0.00012	0.00778	CbGeAlD
Fluoxetine—HTR2A—Amine ligand-binding receptors—HTR1B—migraine	0.000119	0.0075	CbGpPWpGaD
Fluoxetine—HTR2C—head—migraine	0.000118	0.00766	CbGeAlD
Fluoxetine—ALB—Binding and Uptake of Ligands by Scavenger Receptors—LRP1—migraine	0.000115	0.00727	CbGpPWpGaD
Fluoxetine—HTR2A—Monoamine GPCRs—HTR7—migraine	0.000115	0.00726	CbGpPWpGaD
Fluoxetine—HTR2A—Amine ligand-binding receptors—HTR1A—migraine	0.000114	0.00722	CbGpPWpGaD
Fluoxetine—HTR2C—nervous system—migraine	0.000112	0.00727	CbGeAlD
Fluoxetine—SLC6A4—head—migraine	0.000112	0.00726	CbGeAlD
Fluoxetine—HTR2C—Amine ligand-binding receptors—HTR7—migraine	0.000111	0.00703	CbGpPWpGaD
Fluoxetine—HTR2A—Amine ligand-binding receptors—HTR2C—migraine	0.00011	0.00697	CbGpPWpGaD
Fluoxetine—HTR2C—central nervous system—migraine	0.000108	0.007	CbGeAlD
Fluoxetine—CYP2B6—cardiovascular system—migraine	0.000108	0.00696	CbGeAlD
Fluoxetine—HTR2A—brainstem—migraine	0.000108	0.00696	CbGeAlD
Fluoxetine—CYP2C9—cardiovascular system—migraine	0.000107	0.00689	CbGeAlD
Fluoxetine—SLC6A4—nervous system—migraine	0.000106	0.00689	CbGeAlD
Fluoxetine—SLC6A4—central nervous system—migraine	0.000102	0.00663	CbGeAlD
Fluoxetine—Atomoxetine—SLC6A4—migraine	0.000101	0.0669	CrCbGaD
Fluoxetine—SIGMAR1—cerebellum—migraine	9.95e-05	0.00644	CbGeAlD
Fluoxetine—SLC6A2—head—migraine	9.89e-05	0.0064	CbGeAlD
Fluoxetine—CYP2D6—brainstem—migraine	9.79e-05	0.00634	CbGeAlD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—ATP1A3—migraine	9.72e-05	0.00613	CbGpPWpGaD
Fluoxetine—HTR2A—Amine ligand-binding receptors—HTR7—migraine	9.68e-05	0.00611	CbGpPWpGaD
Fluoxetine—SLC6A2—nervous system—migraine	9.37e-05	0.00606	CbGeAlD
Fluoxetine—HTR2C—Monoamine GPCRs—HTR2A—migraine	9.29e-05	0.00586	CbGpPWpGaD
Fluoxetine—SLC6A2—central nervous system—migraine	9.02e-05	0.00584	CbGeAlD
Fluoxetine—HTR2A—cardiovascular system—migraine	8.77e-05	0.00568	CbGeAlD
Fluoxetine—HTR2C—brain—migraine	8.58e-05	0.00555	CbGeAlD
Fluoxetine—ALB—brain—migraine	8.37e-05	0.00542	CbGeAlD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—HTR3A—migraine	8.26e-05	0.00521	CbGpPWpGaD
Fluoxetine—SLC6A4—brain—migraine	8.14e-05	0.00526	CbGeAlD
Fluoxetine—SIGMAR1—brain—migraine	8.08e-05	0.00523	CbGeAlD
Fluoxetine—ABCB1—trigeminal ganglion—migraine	7.96e-05	0.00515	CbGeAlD
Fluoxetine—HTR2C—Amine ligand-binding receptors—HTR2A—migraine	7.81e-05	0.00493	CbGpPWpGaD
Fluoxetine—Atomoxetine—HTR2A—migraine	7.79e-05	0.0514	CrCbGaD
Fluoxetine—CYP1A2—Estrogen Receptor Pathway—ESR1—migraine	7.57e-05	0.00478	CbGpPWpGaD
Fluoxetine—CYP2B6—head—migraine	7.28e-05	0.00471	CbGeAlD
Fluoxetine—SLC6A2—brain—migraine	7.16e-05	0.00464	CbGeAlD
Fluoxetine—CYP2B6—nervous system—migraine	6.91e-05	0.00447	CbGeAlD
Fluoxetine—CYP2B6—central nervous system—migraine	6.65e-05	0.0043	CbGeAlD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—HTR1A—migraine	6.53e-05	0.00412	CbGpPWpGaD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—TAC1—migraine	6.43e-05	0.00406	CbGpPWpGaD
Fluoxetine—HTR2C—G alpha (q) signalling events—HTR2B—migraine	6.24e-05	0.00394	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—TRPM8—migraine	6.19e-05	0.0039	CbGpPWpGaD
Fluoxetine—HTR2A—head—migraine	5.94e-05	0.00384	CbGeAlD
Fluoxetine—SLC6A4—Monoamine Transport—TNF—migraine	5.9e-05	0.00373	CbGpPWpGaD
Fluoxetine—ABCB1—cardiovascular system—migraine	5.75e-05	0.00372	CbGeAlD
Fluoxetine—SLC6A2—NRF2 pathway—SLC6A4—migraine	5.71e-05	0.00361	CbGpPWpGaD
Fluoxetine—HTR2A—GPCRs, Other—EDNRA—migraine	5.68e-05	0.00358	CbGpPWpGaD
Fluoxetine—HTR2A—nervous system—migraine	5.63e-05	0.00364	CbGeAlD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2B—migraine	5.58e-05	0.00352	CbGpPWpGaD
Fluoxetine—HTR2A—central nervous system—migraine	5.42e-05	0.00351	CbGeAlD
Fluoxetine—HTR2A—G alpha (q) signalling events—HTR2B—migraine	5.42e-05	0.00342	CbGpPWpGaD
Fluoxetine—CYP2D6—head—migraine	5.41e-05	0.0035	CbGeAlD
Fluoxetine—HTR2A—cerebellum—migraine	5.3e-05	0.00343	CbGeAlD
Fluoxetine—CYP2B6—brain—migraine	5.28e-05	0.00342	CbGeAlD
Fluoxetine—SLC6A4—Circadian rythm related genes—NPS—migraine	5.25e-05	0.00331	CbGpPWpGaD
Fluoxetine—CYP3A4—nervous system—migraine	5.21e-05	0.00337	CbGeAlD
Fluoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR1D—migraine	5.19e-05	0.00327	CbGpPWpGaD
Fluoxetine—CYP2D6—nervous system—migraine	5.13e-05	0.00332	CbGeAlD
Fluoxetine—HTR2A—GPCRs, Other—HTR7—migraine	5.11e-05	0.00323	CbGpPWpGaD
Fluoxetine—SLC6A2—Monoamine Transport—TNF—migraine	5.08e-05	0.0032	CbGpPWpGaD
Fluoxetine—CYP3A4—central nervous system—migraine	5.02e-05	0.00325	CbGeAlD
Fluoxetine—SLC6A4—NRF2 pathway—TGFBR2—migraine	5.01e-05	0.00316	CbGpPWpGaD
Fluoxetine—CYP2D6—central nervous system—migraine	4.94e-05	0.0032	CbGeAlD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2B—migraine	4.84e-05	0.00306	CbGpPWpGaD
Fluoxetine—CYP2D6—cerebellum—migraine	4.83e-05	0.00312	CbGeAlD
Fluoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2B—migraine	4.82e-05	0.00304	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—ATP1A3—migraine	4.69e-05	0.00296	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—ATP1A2—migraine	4.69e-05	0.00296	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—RAMP1—migraine	4.66e-05	0.00294	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—CALCRL—migraine	4.66e-05	0.00294	CbGpPWpGaD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—BDNF—migraine	4.58e-05	0.00289	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—HTR7—migraine	4.51e-05	0.00284	CbGpPWpGaD
Fluoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—HTR1D—migraine	4.5e-05	0.00284	CbGpPWpGaD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR1D—migraine	4.44e-05	0.0028	CbGpPWpGaD
Fluoxetine—SLC6A2—NRF2 pathway—TGFBR2—migraine	4.31e-05	0.00272	CbGpPWpGaD
Fluoxetine—HTR2A—brain—migraine	4.31e-05	0.00279	CbGeAlD
Fluoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—HTR2B—migraine	4.19e-05	0.00264	CbGpPWpGaD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2B—migraine	4.13e-05	0.00261	CbGpPWpGaD
Fluoxetine—ALB—Vitamin B12 Metabolism—MTHFR—migraine	4.08e-05	0.00258	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—RAMP1—migraine	4.04e-05	0.00255	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—CALCRL—migraine	4.04e-05	0.00255	CbGpPWpGaD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—HTR3A—migraine	3.99e-05	0.00252	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—HTR1A—migraine	3.93e-05	0.00248	CbGpPWpGaD
Fluoxetine—CYP2D6—brain—migraine	3.92e-05	0.00254	CbGeAlD
Fluoxetine—ABCB1—head—migraine	3.89e-05	0.00252	CbGeAlD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—TAC1—migraine	3.87e-05	0.00244	CbGpPWpGaD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—migraine	3.87e-05	0.00244	CbGpPWpGaD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—HTR1D—migraine	3.86e-05	0.00243	CbGpPWpGaD
Fluoxetine—HTR2C—G alpha (q) signalling events—NPS—migraine	3.85e-05	0.00243	CbGpPWpGaD
Fluoxetine—HTR2C—G alpha (q) signalling events—TAC1—migraine	3.85e-05	0.00243	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—SLC6A4—migraine	3.79e-05	0.00239	CbGpPWpGaD
Fluoxetine—ABCB1—nervous system—migraine	3.69e-05	0.00239	CbGeAlD
Fluoxetine—HTR2C—G alpha (q) signalling events—EDNRA—migraine	3.68e-05	0.00232	CbGpPWpGaD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—HTR2B—migraine	3.59e-05	0.00226	CbGpPWpGaD
Fluoxetine—ABCB1—central nervous system—migraine	3.55e-05	0.0023	CbGeAlD
Fluoxetine—ABCB1—cerebellum—migraine	3.47e-05	0.00225	CbGeAlD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—NPS—migraine	3.45e-05	0.00217	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—migraine	3.45e-05	0.00217	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—HTR1D—migraine	3.38e-05	0.00214	CbGpPWpGaD
Fluoxetine—HTR2A—G alpha (q) signalling events—TAC1—migraine	3.35e-05	0.00211	CbGpPWpGaD
Fluoxetine—HTR2A—G alpha (q) signalling events—NPS—migraine	3.35e-05	0.00211	CbGpPWpGaD
Fluoxetine—ALB—Folate Metabolism—MTHFR—migraine	3.32e-05	0.0021	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRA—migraine	3.29e-05	0.00207	CbGpPWpGaD
Fluoxetine—HTR2A—G alpha (q) signalling events—HTR2C—migraine	3.28e-05	0.00207	CbGpPWpGaD
Fluoxetine—HTR2A—G alpha (q) signalling events—EDNRA—migraine	3.19e-05	0.00201	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—HTR2B—migraine	3.15e-05	0.00198	CbGpPWpGaD
Fluoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR1B—migraine	3.14e-05	0.00198	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—TRPM8—migraine	3.11e-05	0.00196	CbGpPWpGaD
Fluoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR1A—migraine	3.02e-05	0.00191	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NPS—migraine	2.99e-05	0.00189	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—migraine	2.99e-05	0.00189	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—HTR1D—migraine	2.94e-05	0.00185	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2C—migraine	2.94e-05	0.00185	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRA—migraine	2.86e-05	0.0018	CbGpPWpGaD
Fluoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—EDNRA—migraine	2.84e-05	0.00179	CbGpPWpGaD
Fluoxetine—ABCB1—brain—migraine	2.82e-05	0.00183	CbGeAlD
Fluoxetine—Chest pain—Valproic Acid—migraine	2.81e-05	0.000353	CcSEcCtD
Fluoxetine—Arthralgia—Valproic Acid—migraine	2.81e-05	0.000353	CcSEcCtD
Fluoxetine—Myalgia—Valproic Acid—migraine	2.81e-05	0.000353	CcSEcCtD
Fluoxetine—Haematuria—Topiramate—migraine	2.81e-05	0.000353	CcSEcCtD
Fluoxetine—Anxiety—Valproic Acid—migraine	2.8e-05	0.000352	CcSEcCtD
Fluoxetine—Hypersensitivity—Verapamil—migraine	2.8e-05	0.000352	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—migraine	2.79e-05	0.000351	CcSEcCtD
Fluoxetine—Epistaxis—Topiramate—migraine	2.78e-05	0.000349	CcSEcCtD
Fluoxetine—Alopecia—Gabapentin—migraine	2.78e-05	0.000349	CcSEcCtD
Fluoxetine—Discomfort—Valproic Acid—migraine	2.78e-05	0.000349	CcSEcCtD
Fluoxetine—Sinusitis—Topiramate—migraine	2.76e-05	0.000347	CcSEcCtD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—migraine	2.76e-05	0.00174	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—BDNF—migraine	2.75e-05	0.00174	CbGpPWpGaD
Fluoxetine—Mental disorder—Gabapentin—migraine	2.75e-05	0.000346	CcSEcCtD
Fluoxetine—Dry mouth—Valproic Acid—migraine	2.75e-05	0.000345	CcSEcCtD
Fluoxetine—Malnutrition—Gabapentin—migraine	2.74e-05	0.000344	CcSEcCtD
Fluoxetine—HTR2A—GPCR ligand binding—HTR2B—migraine	2.73e-05	0.00172	CbGpPWpGaD
Fluoxetine—Dizziness—Propranolol—migraine	2.73e-05	0.000343	CcSEcCtD
Fluoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—HTR1B—migraine	2.73e-05	0.00172	CbGpPWpGaD
Fluoxetine—Asthenia—Verapamil—migraine	2.73e-05	0.000342	CcSEcCtD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—TRPM8—migraine	2.72e-05	0.00172	CbGpPWpGaD
Fluoxetine—Confusional state—Valproic Acid—migraine	2.72e-05	0.000341	CcSEcCtD
Fluoxetine—Flatulence—Gabapentin—migraine	2.7e-05	0.000339	CcSEcCtD
Fluoxetine—Anaphylactic shock—Valproic Acid—migraine	2.69e-05	0.000338	CcSEcCtD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR1B—migraine	2.69e-05	0.0017	CbGpPWpGaD
Fluoxetine—Bradycardia—Topiramate—migraine	2.69e-05	0.000338	CcSEcCtD
Fluoxetine—Pruritus—Verapamil—migraine	2.69e-05	0.000338	CcSEcCtD
Fluoxetine—Tension—Gabapentin—migraine	2.68e-05	0.000337	CcSEcCtD
Fluoxetine—Angioedema—Timolol—migraine	2.68e-05	0.000337	CcSEcCtD
Fluoxetine—Dysgeusia—Gabapentin—migraine	2.68e-05	0.000337	CcSEcCtD
Fluoxetine—Infection—Valproic Acid—migraine	2.68e-05	0.000336	CcSEcCtD
Fluoxetine—Haemoglobin—Topiramate—migraine	2.66e-05	0.000334	CcSEcCtD
Fluoxetine—Nervousness—Gabapentin—migraine	2.66e-05	0.000334	CcSEcCtD
Fluoxetine—Rhinitis—Topiramate—migraine	2.65e-05	0.000333	CcSEcCtD
Fluoxetine—Back pain—Gabapentin—migraine	2.65e-05	0.000332	CcSEcCtD
Fluoxetine—Haemorrhage—Topiramate—migraine	2.64e-05	0.000332	CcSEcCtD
Fluoxetine—Hepatitis—Topiramate—migraine	2.64e-05	0.000332	CcSEcCtD
Fluoxetine—Vertigo—Timolol—migraine	2.64e-05	0.000332	CcSEcCtD
Fluoxetine—ALB—Selenium Micronutrient Network—MTHFR—migraine	2.64e-05	0.00166	CbGpPWpGaD
Fluoxetine—Thrombocytopenia—Valproic Acid—migraine	2.64e-05	0.000331	CcSEcCtD
Fluoxetine—Syncope—Timolol—migraine	2.63e-05	0.000331	CcSEcCtD
Fluoxetine—HTR2C—GPCR downstream signaling—CALCRL—migraine	2.63e-05	0.00166	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—RAMP1—migraine	2.63e-05	0.00166	CbGpPWpGaD
Fluoxetine—Hypoaesthesia—Topiramate—migraine	2.63e-05	0.000331	CcSEcCtD
Fluoxetine—Hallucination—Topiramate—migraine	2.63e-05	0.000331	CcSEcCtD
Fluoxetine—Muscle spasms—Gabapentin—migraine	2.63e-05	0.00033	CcSEcCtD
Fluoxetine—Tachycardia—Valproic Acid—migraine	2.63e-05	0.00033	CcSEcCtD
Fluoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—HTR1A—migraine	2.63e-05	0.00166	CbGpPWpGaD
Fluoxetine—Vomiting—Propranolol—migraine	2.63e-05	0.00033	CcSEcCtD
Fluoxetine—Pharyngitis—Topiramate—migraine	2.62e-05	0.00033	CcSEcCtD
Fluoxetine—Skin disorder—Valproic Acid—migraine	2.62e-05	0.000329	CcSEcCtD
Fluoxetine—Oedema peripheral—Topiramate—migraine	2.6e-05	0.000327	CcSEcCtD
Fluoxetine—Hyperhidrosis—Valproic Acid—migraine	2.6e-05	0.000327	CcSEcCtD
Fluoxetine—Rash—Propranolol—migraine	2.6e-05	0.000327	CcSEcCtD
Fluoxetine—Dermatitis—Propranolol—migraine	2.6e-05	0.000327	CcSEcCtD
Fluoxetine—Diarrhoea—Verapamil—migraine	2.6e-05	0.000327	CcSEcCtD
Fluoxetine—Palpitations—Timolol—migraine	2.6e-05	0.000326	CcSEcCtD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR1A—migraine	2.59e-05	0.00164	CbGpPWpGaD
Fluoxetine—Loss of consciousness—Timolol—migraine	2.58e-05	0.000324	CcSEcCtD
Fluoxetine—Anorexia—Valproic Acid—migraine	2.57e-05	0.000323	CcSEcCtD
Fluoxetine—Cough—Timolol—migraine	2.56e-05	0.000322	CcSEcCtD
Fluoxetine—Tremor—Gabapentin—migraine	2.56e-05	0.000322	CcSEcCtD
Fluoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR7—migraine	2.56e-05	0.00161	CbGpPWpGaD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—TAC1—migraine	2.55e-05	0.00161	CbGpPWpGaD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—NPS—migraine	2.55e-05	0.00161	CbGpPWpGaD
Fluoxetine—Visual impairment—Topiramate—migraine	2.55e-05	0.00032	CcSEcCtD
Fluoxetine—Ill-defined disorder—Gabapentin—migraine	2.54e-05	0.000319	CcSEcCtD
Fluoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—HTR2C—migraine	2.54e-05	0.0016	CbGpPWpGaD
Fluoxetine—Hypertension—Timolol—migraine	2.54e-05	0.000319	CcSEcCtD
Fluoxetine—Anaemia—Gabapentin—migraine	2.53e-05	0.000318	CcSEcCtD
Fluoxetine—Hypotension—Valproic Acid—migraine	2.52e-05	0.000316	CcSEcCtD
Fluoxetine—Agitation—Gabapentin—migraine	2.51e-05	0.000316	CcSEcCtD
Fluoxetine—Dizziness—Verapamil—migraine	2.51e-05	0.000316	CcSEcCtD
Fluoxetine—Myalgia—Timolol—migraine	2.5e-05	0.000314	CcSEcCtD
Fluoxetine—Chest pain—Timolol—migraine	2.5e-05	0.000314	CcSEcCtD
Fluoxetine—Arthralgia—Timolol—migraine	2.5e-05	0.000314	CcSEcCtD
Fluoxetine—Erythema multiforme—Topiramate—migraine	2.5e-05	0.000314	CcSEcCtD
Fluoxetine—Angioedema—Gabapentin—migraine	2.5e-05	0.000314	CcSEcCtD
Fluoxetine—Anxiety—Timolol—migraine	2.49e-05	0.000313	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Timolol—migraine	2.48e-05	0.000312	CcSEcCtD
Fluoxetine—Discomfort—Timolol—migraine	2.47e-05	0.00031	CcSEcCtD
Fluoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—EDNRA—migraine	2.47e-05	0.00156	CbGpPWpGaD
Fluoxetine—Malaise—Gabapentin—migraine	2.47e-05	0.00031	CcSEcCtD
Fluoxetine—Tinnitus—Topiramate—migraine	2.46e-05	0.00031	CcSEcCtD
Fluoxetine—Vertigo—Gabapentin—migraine	2.46e-05	0.000309	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Valproic Acid—migraine	2.45e-05	0.000308	CcSEcCtD
Fluoxetine—Syncope—Gabapentin—migraine	2.45e-05	0.000308	CcSEcCtD
Fluoxetine—Nausea—Propranolol—migraine	2.45e-05	0.000308	CcSEcCtD
Fluoxetine—Leukopenia—Gabapentin—migraine	2.45e-05	0.000308	CcSEcCtD
Fluoxetine—Dry mouth—Timolol—migraine	2.45e-05	0.000307	CcSEcCtD
Fluoxetine—Insomnia—Valproic Acid—migraine	2.44e-05	0.000306	CcSEcCtD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—EDNRA—migraine	2.43e-05	0.00154	CbGpPWpGaD
Fluoxetine—Paraesthesia—Valproic Acid—migraine	2.42e-05	0.000304	CcSEcCtD
Fluoxetine—Palpitations—Gabapentin—migraine	2.42e-05	0.000304	CcSEcCtD
Fluoxetine—Confusional state—Timolol—migraine	2.42e-05	0.000304	CcSEcCtD
Fluoxetine—Vomiting—Verapamil—migraine	2.41e-05	0.000303	CcSEcCtD
Fluoxetine—Loss of consciousness—Gabapentin—migraine	2.4e-05	0.000302	CcSEcCtD
Fluoxetine—Dyspnoea—Valproic Acid—migraine	2.4e-05	0.000302	CcSEcCtD
Fluoxetine—Anaphylactic shock—Timolol—migraine	2.4e-05	0.000301	CcSEcCtD
Fluoxetine—Rash—Verapamil—migraine	2.39e-05	0.000301	CcSEcCtD
Fluoxetine—Somnolence—Valproic Acid—migraine	2.39e-05	0.000301	CcSEcCtD
Fluoxetine—Dermatitis—Verapamil—migraine	2.39e-05	0.000301	CcSEcCtD
Fluoxetine—HTR2C—Signaling by GPCR—CALCRL—migraine	2.39e-05	0.00151	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—RAMP1—migraine	2.39e-05	0.00151	CbGpPWpGaD
Fluoxetine—Cough—Gabapentin—migraine	2.39e-05	0.0003	CcSEcCtD
Fluoxetine—Infection—Timolol—migraine	2.38e-05	0.000299	CcSEcCtD
Fluoxetine—Headache—Verapamil—migraine	2.38e-05	0.000299	CcSEcCtD
Fluoxetine—Chills—Topiramate—migraine	2.37e-05	0.000298	CcSEcCtD
Fluoxetine—Dyspepsia—Valproic Acid—migraine	2.37e-05	0.000298	CcSEcCtD
Fluoxetine—Convulsion—Gabapentin—migraine	2.37e-05	0.000298	CcSEcCtD
Fluoxetine—Hypertension—Gabapentin—migraine	2.36e-05	0.000297	CcSEcCtD
Fluoxetine—Shock—Timolol—migraine	2.36e-05	0.000296	CcSEcCtD
Fluoxetine—ALB—Transmembrane transport of small molecules—ATP1A2—migraine	2.36e-05	0.00149	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—ATP1A3—migraine	2.36e-05	0.00149	CbGpPWpGaD
Fluoxetine—Decreased appetite—Valproic Acid—migraine	2.34e-05	0.000294	CcSEcCtD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—HTR1B—migraine	2.34e-05	0.00148	CbGpPWpGaD
Fluoxetine—Alopecia—Topiramate—migraine	2.34e-05	0.000294	CcSEcCtD
Fluoxetine—ABCB1—HIF-1-alpha transcription factor network—FOS—migraine	2.33e-05	0.00147	CbGpPWpGaD
Fluoxetine—Arthralgia—Gabapentin—migraine	2.33e-05	0.000293	CcSEcCtD
Fluoxetine—Myalgia—Gabapentin—migraine	2.33e-05	0.000293	CcSEcCtD
Fluoxetine—Chest pain—Gabapentin—migraine	2.33e-05	0.000293	CcSEcCtD
Fluoxetine—Skin disorder—Timolol—migraine	2.33e-05	0.000293	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Valproic Acid—migraine	2.32e-05	0.000292	CcSEcCtD
Fluoxetine—Fatigue—Valproic Acid—migraine	2.32e-05	0.000292	CcSEcCtD
Fluoxetine—Anxiety—Gabapentin—migraine	2.32e-05	0.000292	CcSEcCtD
Fluoxetine—HTR2C—G alpha (q) signalling events—HTR2A—migraine	2.32e-05	0.00146	CbGpPWpGaD
Fluoxetine—Hyperhidrosis—Timolol—migraine	2.32e-05	0.000291	CcSEcCtD
Fluoxetine—Mental disorder—Topiramate—migraine	2.32e-05	0.000291	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—migraine	2.31e-05	0.000291	CcSEcCtD
Fluoxetine—Constipation—Valproic Acid—migraine	2.3e-05	0.000289	CcSEcCtD
Fluoxetine—Pain—Valproic Acid—migraine	2.3e-05	0.000289	CcSEcCtD
Fluoxetine—Malnutrition—Topiramate—migraine	2.3e-05	0.000289	CcSEcCtD
Fluoxetine—Discomfort—Gabapentin—migraine	2.3e-05	0.000289	CcSEcCtD
Fluoxetine—HTR2A—GPCR downstream signaling—CALCRL—migraine	2.29e-05	0.00144	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—RAMP1—migraine	2.29e-05	0.00144	CbGpPWpGaD
Fluoxetine—Anorexia—Timolol—migraine	2.29e-05	0.000287	CcSEcCtD
Fluoxetine—Dry mouth—Gabapentin—migraine	2.28e-05	0.000286	CcSEcCtD
Fluoxetine—Flatulence—Topiramate—migraine	2.27e-05	0.000285	CcSEcCtD
Fluoxetine—Tension—Topiramate—migraine	2.26e-05	0.000284	CcSEcCtD
Fluoxetine—Nausea—Verapamil—migraine	2.26e-05	0.000283	CcSEcCtD
Fluoxetine—Dysgeusia—Topiramate—migraine	2.25e-05	0.000283	CcSEcCtD
Fluoxetine—Confusional state—Gabapentin—migraine	2.25e-05	0.000283	CcSEcCtD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—HTR1A—migraine	2.25e-05	0.00142	CbGpPWpGaD
Fluoxetine—Hypotension—Timolol—migraine	2.24e-05	0.000281	CcSEcCtD
Fluoxetine—Nervousness—Topiramate—migraine	2.24e-05	0.000281	CcSEcCtD
Fluoxetine—Anaphylactic shock—Gabapentin—migraine	2.23e-05	0.000281	CcSEcCtD
Fluoxetine—Back pain—Topiramate—migraine	2.23e-05	0.00028	CcSEcCtD
Fluoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—HTR7—migraine	2.22e-05	0.0014	CbGpPWpGaD
Fluoxetine—Feeling abnormal—Valproic Acid—migraine	2.22e-05	0.000279	CcSEcCtD
Fluoxetine—Infection—Gabapentin—migraine	2.22e-05	0.000279	CcSEcCtD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—NPS—migraine	2.22e-05	0.0014	CbGpPWpGaD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—TAC1—migraine	2.22e-05	0.0014	CbGpPWpGaD
Fluoxetine—Muscle spasms—Topiramate—migraine	2.21e-05	0.000278	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Valproic Acid—migraine	2.2e-05	0.000277	CcSEcCtD
Fluoxetine—Shock—Gabapentin—migraine	2.2e-05	0.000276	CcSEcCtD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR7—migraine	2.19e-05	0.00138	CbGpPWpGaD
Fluoxetine—Thrombocytopenia—Gabapentin—migraine	2.19e-05	0.000275	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Timolol—migraine	2.18e-05	0.000274	CcSEcCtD
Fluoxetine—Tachycardia—Gabapentin—migraine	2.18e-05	0.000274	CcSEcCtD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—HTR2C—migraine	2.17e-05	0.00137	CbGpPWpGaD
Fluoxetine—Skin disorder—Gabapentin—migraine	2.17e-05	0.000272	CcSEcCtD
Fluoxetine—Insomnia—Timolol—migraine	2.17e-05	0.000272	CcSEcCtD
Fluoxetine—Hyperhidrosis—Gabapentin—migraine	2.16e-05	0.000271	CcSEcCtD
Fluoxetine—Tremor—Topiramate—migraine	2.16e-05	0.000271	CcSEcCtD
Fluoxetine—Paraesthesia—Timolol—migraine	2.15e-05	0.00027	CcSEcCtD
Fluoxetine—Urticaria—Valproic Acid—migraine	2.14e-05	0.000269	CcSEcCtD
Fluoxetine—Dyspnoea—Timolol—migraine	2.14e-05	0.000269	CcSEcCtD
Fluoxetine—Ill-defined disorder—Topiramate—migraine	2.14e-05	0.000268	CcSEcCtD
Fluoxetine—Somnolence—Timolol—migraine	2.13e-05	0.000268	CcSEcCtD
Fluoxetine—Abdominal pain—Valproic Acid—migraine	2.13e-05	0.000268	CcSEcCtD
Fluoxetine—Body temperature increased—Valproic Acid—migraine	2.13e-05	0.000268	CcSEcCtD
Fluoxetine—Anorexia—Gabapentin—migraine	2.13e-05	0.000267	CcSEcCtD
Fluoxetine—Anaemia—Topiramate—migraine	2.13e-05	0.000267	CcSEcCtD
Fluoxetine—Agitation—Topiramate—migraine	2.11e-05	0.000266	CcSEcCtD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—EDNRA—migraine	2.11e-05	0.00133	CbGpPWpGaD
Fluoxetine—Dyspepsia—Timolol—migraine	2.11e-05	0.000265	CcSEcCtD
Fluoxetine—Hypotension—Gabapentin—migraine	2.09e-05	0.000262	CcSEcCtD
Fluoxetine—Decreased appetite—Timolol—migraine	2.08e-05	0.000262	CcSEcCtD
Fluoxetine—Malaise—Topiramate—migraine	2.08e-05	0.000261	CcSEcCtD
Fluoxetine—HTR2A—Signaling by GPCR—CALCRL—migraine	2.08e-05	0.00131	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—RAMP1—migraine	2.08e-05	0.00131	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—migraine	2.07e-05	0.00131	CbGpPWpGaD
Fluoxetine—Gastrointestinal disorder—Timolol—migraine	2.07e-05	0.00026	CcSEcCtD
Fluoxetine—Vertigo—Topiramate—migraine	2.07e-05	0.00026	CcSEcCtD
Fluoxetine—Fatigue—Timolol—migraine	2.07e-05	0.00026	CcSEcCtD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—ATP1A3—migraine	2.06e-05	0.0013	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—ATP1A2—migraine	2.06e-05	0.0013	CbGpPWpGaD
Fluoxetine—Syncope—Topiramate—migraine	2.06e-05	0.000259	CcSEcCtD
Fluoxetine—Leukopenia—Topiramate—migraine	2.06e-05	0.000259	CcSEcCtD
Fluoxetine—Pain—Timolol—migraine	2.05e-05	0.000258	CcSEcCtD
Fluoxetine—HTR2C—GPCR ligand binding—HTR1B—migraine	2.05e-05	0.00129	CbGpPWpGaD
Fluoxetine—Musculoskeletal discomfort—Gabapentin—migraine	2.03e-05	0.000256	CcSEcCtD
Fluoxetine—Palpitations—Topiramate—migraine	2.03e-05	0.000256	CcSEcCtD
Fluoxetine—Loss of consciousness—Topiramate—migraine	2.02e-05	0.000254	CcSEcCtD
Fluoxetine—Insomnia—Gabapentin—migraine	2.02e-05	0.000254	CcSEcCtD
Fluoxetine—Cough—Topiramate—migraine	2.01e-05	0.000252	CcSEcCtD
Fluoxetine—Paraesthesia—Gabapentin—migraine	2e-05	0.000252	CcSEcCtD
Fluoxetine—ALB—Transmembrane transport of small molecules—HTR3A—migraine	2e-05	0.00126	CbGpPWpGaD
Fluoxetine—Convulsion—Topiramate—migraine	1.99e-05	0.000251	CcSEcCtD
Fluoxetine—Dyspnoea—Gabapentin—migraine	1.99e-05	0.00025	CcSEcCtD
Fluoxetine—Hypertension—Topiramate—migraine	1.99e-05	0.00025	CcSEcCtD
Fluoxetine—Somnolence—Gabapentin—migraine	1.98e-05	0.000249	CcSEcCtD
Fluoxetine—Hypersensitivity—Valproic Acid—migraine	1.98e-05	0.000249	CcSEcCtD
Fluoxetine—Feeling abnormal—Timolol—migraine	1.98e-05	0.000248	CcSEcCtD
Fluoxetine—HTR2C—GPCR ligand binding—HTR1A—migraine	1.97e-05	0.00125	CbGpPWpGaD
Fluoxetine—Dyspepsia—Gabapentin—migraine	1.97e-05	0.000247	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Timolol—migraine	1.96e-05	0.000246	CcSEcCtD
Fluoxetine—Arthralgia—Topiramate—migraine	1.96e-05	0.000246	CcSEcCtD
Fluoxetine—Chest pain—Topiramate—migraine	1.96e-05	0.000246	CcSEcCtD
Fluoxetine—Myalgia—Topiramate—migraine	1.96e-05	0.000246	CcSEcCtD
Fluoxetine—Anxiety—Topiramate—migraine	1.95e-05	0.000245	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Topiramate—migraine	1.95e-05	0.000244	CcSEcCtD
Fluoxetine—HTR2C—GPCR ligand binding—NPS—migraine	1.94e-05	0.00123	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—TAC1—migraine	1.94e-05	0.00123	CbGpPWpGaD
Fluoxetine—Decreased appetite—Gabapentin—migraine	1.94e-05	0.000244	CcSEcCtD
Fluoxetine—Discomfort—Topiramate—migraine	1.94e-05	0.000243	CcSEcCtD
Fluoxetine—Asthenia—Valproic Acid—migraine	1.93e-05	0.000243	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Gabapentin—migraine	1.93e-05	0.000242	CcSEcCtD
Fluoxetine—Fatigue—Gabapentin—migraine	1.92e-05	0.000242	CcSEcCtD
Fluoxetine—Dry mouth—Topiramate—migraine	1.92e-05	0.000241	CcSEcCtD
Fluoxetine—HTR2C—GPCR downstream signaling—HTR1D—migraine	1.91e-05	0.00121	CbGpPWpGaD
Fluoxetine—Constipation—Gabapentin—migraine	1.91e-05	0.00024	CcSEcCtD
Fluoxetine—Pain—Gabapentin—migraine	1.91e-05	0.00024	CcSEcCtD
Fluoxetine—Pruritus—Valproic Acid—migraine	1.91e-05	0.000239	CcSEcCtD
Fluoxetine—Urticaria—Timolol—migraine	1.9e-05	0.000239	CcSEcCtD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—HTR7—migraine	1.9e-05	0.0012	CbGpPWpGaD
Fluoxetine—Abdominal pain—Timolol—migraine	1.9e-05	0.000238	CcSEcCtD
Fluoxetine—Body temperature increased—Timolol—migraine	1.9e-05	0.000238	CcSEcCtD
Fluoxetine—Confusional state—Topiramate—migraine	1.89e-05	0.000238	CcSEcCtD
Fluoxetine—Infection—Topiramate—migraine	1.87e-05	0.000234	CcSEcCtD
Fluoxetine—HTR2C—GPCR ligand binding—EDNRA—migraine	1.85e-05	0.00117	CbGpPWpGaD
Fluoxetine—Shock—Topiramate—migraine	1.85e-05	0.000232	CcSEcCtD
Fluoxetine—Diarrhoea—Valproic Acid—migraine	1.84e-05	0.000232	CcSEcCtD
Fluoxetine—Feeling abnormal—Gabapentin—migraine	1.84e-05	0.000231	CcSEcCtD
Fluoxetine—Thrombocytopenia—Topiramate—migraine	1.84e-05	0.000231	CcSEcCtD
Fluoxetine—Tachycardia—Topiramate—migraine	1.83e-05	0.00023	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Gabapentin—migraine	1.83e-05	0.000229	CcSEcCtD
Fluoxetine—Skin disorder—Topiramate—migraine	1.82e-05	0.000229	CcSEcCtD
Fluoxetine—Hyperhidrosis—Topiramate—migraine	1.82e-05	0.000228	CcSEcCtD
Fluoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—migraine	1.79e-05	0.00113	CbGpPWpGaD
Fluoxetine—Anorexia—Topiramate—migraine	1.79e-05	0.000225	CcSEcCtD
Fluoxetine—HTR2C—GPCR ligand binding—CALCA—migraine	1.78e-05	0.00113	CbGpPWpGaD
Fluoxetine—Dizziness—Valproic Acid—migraine	1.78e-05	0.000224	CcSEcCtD
Fluoxetine—HTR2A—GPCR ligand binding—HTR1B—migraine	1.78e-05	0.00112	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—HTR2B—migraine	1.78e-05	0.00112	CbGpPWpGaD
Fluoxetine—Urticaria—Gabapentin—migraine	1.77e-05	0.000223	CcSEcCtD
Fluoxetine—Hypersensitivity—Timolol—migraine	1.77e-05	0.000222	CcSEcCtD
Fluoxetine—Body temperature increased—Gabapentin—migraine	1.76e-05	0.000222	CcSEcCtD
Fluoxetine—Abdominal pain—Gabapentin—migraine	1.76e-05	0.000222	CcSEcCtD
Fluoxetine—ALB—Vitamin B12 Metabolism—TNF—migraine	1.76e-05	0.00111	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—HTR3A—migraine	1.76e-05	0.00111	CbGpPWpGaD
Fluoxetine—Hypotension—Topiramate—migraine	1.76e-05	0.000221	CcSEcCtD
Fluoxetine—HTR2C—Signaling by GPCR—HTR1D—migraine	1.74e-05	0.0011	CbGpPWpGaD
Fluoxetine—Asthenia—Timolol—migraine	1.72e-05	0.000216	CcSEcCtD
Fluoxetine—HTR2A—GPCR ligand binding—HTR1A—migraine	1.71e-05	0.00108	CbGpPWpGaD
Fluoxetine—Vomiting—Valproic Acid—migraine	1.71e-05	0.000215	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Topiramate—migraine	1.71e-05	0.000215	CcSEcCtD
Fluoxetine—Insomnia—Topiramate—migraine	1.7e-05	0.000213	CcSEcCtD
Fluoxetine—Rash—Valproic Acid—migraine	1.7e-05	0.000213	CcSEcCtD
Fluoxetine—Dermatitis—Valproic Acid—migraine	1.7e-05	0.000213	CcSEcCtD
Fluoxetine—Pruritus—Timolol—migraine	1.7e-05	0.000213	CcSEcCtD
Fluoxetine—HTR2A—GPCR ligand binding—TAC1—migraine	1.69e-05	0.00106	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—NPS—migraine	1.69e-05	0.00106	CbGpPWpGaD
Fluoxetine—Headache—Valproic Acid—migraine	1.69e-05	0.000212	CcSEcCtD
Fluoxetine—Paraesthesia—Topiramate—migraine	1.69e-05	0.000212	CcSEcCtD
Fluoxetine—Dyspnoea—Topiramate—migraine	1.67e-05	0.00021	CcSEcCtD
Fluoxetine—Somnolence—Topiramate—migraine	1.67e-05	0.00021	CcSEcCtD
Fluoxetine—HTR2C—GPCR ligand binding—HTR7—migraine	1.67e-05	0.00105	CbGpPWpGaD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—migraine	1.66e-05	0.00105	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—HTR1D—migraine	1.66e-05	0.00105	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—HTR2C—migraine	1.66e-05	0.00104	CbGpPWpGaD
Fluoxetine—Dyspepsia—Topiramate—migraine	1.65e-05	0.000208	CcSEcCtD
Fluoxetine—Hypersensitivity—Gabapentin—migraine	1.64e-05	0.000207	CcSEcCtD
Fluoxetine—Diarrhoea—Timolol—migraine	1.64e-05	0.000206	CcSEcCtD
Fluoxetine—Decreased appetite—Topiramate—migraine	1.63e-05	0.000205	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Topiramate—migraine	1.62e-05	0.000204	CcSEcCtD
Fluoxetine—Fatigue—Topiramate—migraine	1.62e-05	0.000203	CcSEcCtD
Fluoxetine—HTR2C—Signaling by GPCR—HTR2B—migraine	1.61e-05	0.00102	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—EDNRA—migraine	1.61e-05	0.00102	CbGpPWpGaD
Fluoxetine—Pain—Topiramate—migraine	1.61e-05	0.000202	CcSEcCtD
Fluoxetine—Constipation—Topiramate—migraine	1.61e-05	0.000202	CcSEcCtD
Fluoxetine—Asthenia—Gabapentin—migraine	1.6e-05	0.000201	CcSEcCtD
Fluoxetine—Nausea—Valproic Acid—migraine	1.6e-05	0.000201	CcSEcCtD
Fluoxetine—Dizziness—Timolol—migraine	1.59e-05	0.000199	CcSEcCtD
Fluoxetine—Pruritus—Gabapentin—migraine	1.58e-05	0.000198	CcSEcCtD
Fluoxetine—HTR2A—GPCR ligand binding—CALCA—migraine	1.55e-05	0.000978	CbGpPWpGaD
Fluoxetine—Feeling abnormal—Topiramate—migraine	1.55e-05	0.000194	CcSEcCtD
Fluoxetine—HTR2A—GPCR downstream signaling—HTR2B—migraine	1.54e-05	0.000974	CbGpPWpGaD
Fluoxetine—Gastrointestinal pain—Topiramate—migraine	1.54e-05	0.000193	CcSEcCtD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—migraine	1.54e-05	0.000969	CbGpPWpGaD
Fluoxetine—Diarrhoea—Gabapentin—migraine	1.53e-05	0.000192	CcSEcCtD
Fluoxetine—Vomiting—Timolol—migraine	1.52e-05	0.000192	CcSEcCtD
Fluoxetine—Rash—Timolol—migraine	1.51e-05	0.00019	CcSEcCtD
Fluoxetine—Dermatitis—Timolol—migraine	1.51e-05	0.00019	CcSEcCtD
Fluoxetine—HTR2A—Signaling by GPCR—HTR1D—migraine	1.51e-05	0.000951	CbGpPWpGaD
Fluoxetine—Headache—Timolol—migraine	1.5e-05	0.000189	CcSEcCtD
Fluoxetine—Urticaria—Topiramate—migraine	1.49e-05	0.000187	CcSEcCtD
Fluoxetine—Abdominal pain—Topiramate—migraine	1.48e-05	0.000187	CcSEcCtD
Fluoxetine—Body temperature increased—Topiramate—migraine	1.48e-05	0.000187	CcSEcCtD
Fluoxetine—Dizziness—Gabapentin—migraine	1.48e-05	0.000186	CcSEcCtD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—migraine	1.47e-05	0.00093	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—HTR7—migraine	1.45e-05	0.000915	CbGpPWpGaD
Fluoxetine—ALB—Folate Metabolism—TNF—migraine	1.43e-05	0.000902	CbGpPWpGaD
Fluoxetine—Nausea—Timolol—migraine	1.42e-05	0.000179	CcSEcCtD
Fluoxetine—Vomiting—Gabapentin—migraine	1.42e-05	0.000178	CcSEcCtD
Fluoxetine—HTR2C—Signaling Pathways—CALCRL—migraine	1.41e-05	0.000891	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—RAMP1—migraine	1.41e-05	0.000891	CbGpPWpGaD
Fluoxetine—Rash—Gabapentin—migraine	1.41e-05	0.000177	CcSEcCtD
Fluoxetine—Dermatitis—Gabapentin—migraine	1.41e-05	0.000177	CcSEcCtD
Fluoxetine—HTR2A—Signaling by GPCR—HTR2B—migraine	1.4e-05	0.000885	CbGpPWpGaD
Fluoxetine—Headache—Gabapentin—migraine	1.4e-05	0.000176	CcSEcCtD
Fluoxetine—Hypersensitivity—Topiramate—migraine	1.38e-05	0.000174	CcSEcCtD
Fluoxetine—Asthenia—Topiramate—migraine	1.35e-05	0.000169	CcSEcCtD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—migraine	1.34e-05	0.000842	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—migraine	1.34e-05	0.000842	CbGpPWpGaD
Fluoxetine—Pruritus—Topiramate—migraine	1.33e-05	0.000167	CcSEcCtD
Fluoxetine—Nausea—Gabapentin—migraine	1.33e-05	0.000167	CcSEcCtD
Fluoxetine—Diarrhoea—Topiramate—migraine	1.29e-05	0.000161	CcSEcCtD
Fluoxetine—Dizziness—Topiramate—migraine	1.24e-05	0.000156	CcSEcCtD
Fluoxetine—HTR2A—Signaling Pathways—RAMP1—migraine	1.23e-05	0.000774	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CALCRL—migraine	1.23e-05	0.000774	CbGpPWpGaD
Fluoxetine—Vomiting—Topiramate—migraine	1.19e-05	0.00015	CcSEcCtD
Fluoxetine—Rash—Topiramate—migraine	1.18e-05	0.000149	CcSEcCtD
Fluoxetine—Dermatitis—Topiramate—migraine	1.18e-05	0.000149	CcSEcCtD
Fluoxetine—Headache—Topiramate—migraine	1.18e-05	0.000148	CcSEcCtD
Fluoxetine—HTR2C—GPCR ligand binding—HTR2A—migraine	1.17e-05	0.000738	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—HTR1B—migraine	1.16e-05	0.000731	CbGpPWpGaD
Fluoxetine—ALB—Selenium Micronutrient Network—TNF—migraine	1.14e-05	0.000717	CbGpPWpGaD
Fluoxetine—Nausea—Topiramate—migraine	1.12e-05	0.00014	CcSEcCtD
Fluoxetine—HTR2C—GPCR downstream signaling—HTR1A—migraine	1.12e-05	0.000704	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—migraine	1.11e-05	0.000697	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—TAC1—migraine	1.1e-05	0.000693	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—NPS—migraine	1.1e-05	0.000693	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—TNF—migraine	1.09e-05	0.000685	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—HTR1B—migraine	1.05e-05	0.000664	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—EDNRA—migraine	1.05e-05	0.000661	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HTR1D—migraine	1.03e-05	0.000647	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—HTR1A—migraine	1.01e-05	0.000639	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—CALCA—migraine	1.01e-05	0.000636	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—HTR1B—migraine	1.01e-05	0.000635	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—TNF—migraine	1e-05	0.000631	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—NPS—migraine	9.97e-06	0.000629	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—TAC1—migraine	9.97e-06	0.000629	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—HTR1A—migraine	9.68e-06	0.000611	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—TAC1—migraine	9.54e-06	0.000602	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—NPS—migraine	9.54e-06	0.000602	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HTR2B—migraine	9.54e-06	0.000602	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—EDNRA—migraine	9.51e-06	0.0006	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CACNA1A—migraine	9.48e-06	0.000598	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—HTR7—migraine	9.43e-06	0.000595	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—HTR2C—migraine	9.35e-06	0.00059	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CACNA1A—migraine	9.26e-06	0.000585	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—CALCA—migraine	9.16e-06	0.000578	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—HTR1B—migraine	9.14e-06	0.000576	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—EDNRA—migraine	9.1e-06	0.000574	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HTR1D—migraine	8.91e-06	0.000562	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—HTR1A—migraine	8.79e-06	0.000555	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—CALCA—migraine	8.76e-06	0.000553	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—NPS—migraine	8.66e-06	0.000546	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—TAC1—migraine	8.66e-06	0.000546	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—HTR7—migraine	8.57e-06	0.000541	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—HTR2C—migraine	8.49e-06	0.000536	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—LRP1—migraine	8.4e-06	0.00053	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HTR2B—migraine	8.28e-06	0.000523	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—EDNRA—migraine	8.26e-06	0.000521	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—HTR7—migraine	8.19e-06	0.000517	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CACNA1A—migraine	7.98e-06	0.000503	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CALCA—migraine	7.95e-06	0.000502	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—HTR7—migraine	7.44e-06	0.000469	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—LRP1—migraine	7.29e-06	0.00046	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CACNA1A—migraine	7.16e-06	0.000452	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CACNA1A—migraine	6.99e-06	0.000441	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—HTR2A—migraine	6.61e-06	0.000417	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CACNA1A—migraine	6.59e-06	0.000416	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CACNA1A—migraine	6.53e-06	0.000412	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NOTCH4—migraine	6.44e-06	0.000406	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HTR1B—migraine	6.21e-06	0.000392	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—HTR2A—migraine	6e-06	0.000379	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HTR1A—migraine	5.98e-06	0.000377	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TAC1—migraine	5.89e-06	0.000372	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NPS—migraine	5.89e-06	0.000372	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PGR—migraine	5.89e-06	0.000372	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EDNRA—migraine	5.62e-06	0.000355	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NOTCH4—migraine	5.59e-06	0.000353	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CACNA1A—migraine	5.58e-06	0.000352	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NOTCH3—migraine	5.48e-06	0.000346	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CALCA—migraine	5.41e-06	0.000341	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HTR1B—migraine	5.4e-06	0.000341	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—migraine	5.35e-06	0.000338	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HTR1A—migraine	5.19e-06	0.000328	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PGR—migraine	5.12e-06	0.000323	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NPS—migraine	5.12e-06	0.000323	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TAC1—migraine	5.12e-06	0.000323	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HTR7—migraine	5.06e-06	0.000319	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HTR2C—migraine	5.02e-06	0.000317	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EDNRA—migraine	4.88e-06	0.000308	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NOTCH3—migraine	4.76e-06	0.0003	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CALCA—migraine	4.7e-06	0.000296	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HTR7—migraine	4.39e-06	0.000277	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TGFBR2—migraine	4.36e-06	0.000275	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CACNA1A—migraine	4.31e-06	0.000272	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TGFBR2—migraine	3.78e-06	0.000239	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HTR2A—migraine	3.54e-06	0.000224	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ESR1—migraine	3.15e-06	0.000198	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—MTHFR—migraine	3.14e-06	0.000198	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—MTHFR—migraine	3.06e-06	0.000193	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ESR1—migraine	2.73e-06	0.000172	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—MTHFR—migraine	2.64e-06	0.000167	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—MTHFR—migraine	2.37e-06	0.000149	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—MTHFR—migraine	2.31e-06	0.000146	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—MTHFR—migraine	2.18e-06	0.000137	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—MTHFR—migraine	2.16e-06	0.000136	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—MTHFR—migraine	1.85e-06	0.000116	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—MTHFR—migraine	1.42e-06	8.99e-05	CbGpPWpGaD
